주요성과

• 논문 목록
  • 2024년
  • 2023년
  • 2022년
  • 2021년

  해당 관련 논문목록과 초록보기 링크 제공

  Long-term humoral and cellular immunity against vaccine strains and Omicron subvariants (BQ.1.1, BN.1, XBB.1, and EG.5) after bivalent COVID-19 vaccination Frontiers in Immunology, 2024, 15: 1385135.	초록보기
  Immunogenicity and safety of concomitant bivalent COVID-19 and quadrivalent influenza vaccination: implications of immune imprinting and interference Clinical Microbiology and Infection, 2024, 30.5: 653-659.	초록보기

  해당 관련 논문목록과 초록보기 링크 제공

  Six-Month Longitudinal Immune Kinetics After mRNA-1273 Vaccination: Correlation of Peak Antibody Response with Long-Term, Cross-Reactive Immunity Frontiers in Immunology, 2023, 13: 1035441.	초록보기
  Predictive Value of Reactogenicity for Anti-SARS-CoV-2 Antibody Response in mRNA-1273 Recipients: A Multicenter Prospective Cohort Study Vaccines, 2023, 11.1: 120.	초록보기
  Early countermeasures to COVID-19 at long-term care facilities in Gwangju Metropolitan City, Republic of Korea Osong Public Health and Research Perspectives, 2023, 14.1: 59.	초록보기
  Cross-neutralization of Omicron subvariants after heterologous NVX-CoV2373 boosters: Comparison between prior SARS-CoV-2-infected and infection-naive individuals The Journal of infection, 2023, 86.2: e46.	초록보기
  Neutralizing Activity against BQ.1.1, BN.1, and XBB.1 in Bivalent COVID-19 Vaccine Recipients: Comparison by the Types of Prior Infection and Vaccine Formulations Vaccines, 2023, 11.8: 1320.	초록보기
  Korea Seroprevalence study of Monitoring of SARS-CoV-2 Antibody Retention and Transmission(K-Serosmart) : findings from national representative sample Epidemiology and health, 2023, 45.	초록보기
  Longitudinal kinetics of neutralizing antibodies against circulating SARS-CoV-2 variants and estimated level of group immunity of booster-vaccinated individuals during omicron- dominated COVID-19 outbreaks in the Republic of Korea, 2022 Microbiology Spectrum, 2023, 11.5: e01655-23.	초록보기
  Evolution of neutralizing antibodies through vaccination and breakthrough infections in the era of COVID-19 endemicity Journal of Medical Virology, 2023, 95.12: e29285.	초록보기
  Clinical utility of quantitative immunoassays and surrogate virus neutralization tests for predicting neutralizing activity against the SARS‐CoV‐2 Omicron BA.1 and BA.5 variants Journal of Medical Virology, 2023, 95.12: e29329.	초록보기
  Pediatric humoral immune responses and infection risk after severe acute respirtory syndrome coronavirus 2(SARS-CoV-2) infection and two-dose vaccination during SARS-Co-V2 omicron BA.5 and BN.1 variants predominance in South korea. Longitudinal immune kinetics of COVID-19 booster versus primary series vaccination: Insight into the annual vaccination strategy Frontiers in Immunology, 2023, 14: 1306604.	초록보기

  해당 관련 논문목록과 초록보기 링크 제공

  Performance Comparison of Five SARS-CoV-2 Antibody Assays for Seroprevalence Studies Annals of laboratory medicine, 2022, 42.1: 71-78.	초록보기
  Heterologous ChAdOx1 and BNT162b2 vaccination induces strong neutralizing antibody responses against SARS-CoV-2 including delta variant with tolerable reactogenicity Clinical Microbiology and Infection, 2022, 28.10: 1390. e1-1390. e7.	초록보기
  Neutralizing Activity Against SARSCoV-2 Delta and Omicron Variants Following a Third BNT162b2 Booster Dose According to Three Homologous or Heterologous COVID-19 Vaccination Schedules Frontiers in Cellular and Infection Microbiology, 2022, 12: 948014.	초록보기
  COVID-19 vaccine type-dependent differences in immunogenicity and inflammatory response: BNT162b2 and ChAdOx1 nCoV-19 Frontiers in Immunology, 2022, 13: 975363.	초록보기
  Immunogenicity and reactogenicity of Ad26. COV2. S: a prospective cohort study. Infection & Chemotherapy, 2022, 54.	초록보기
  Kinetics of vaccine-induced neutralizing antibody titers and estimated protective immunity against wild-type SARS-CoV-2 and the Delta variant: A prospective nationwide cohort study comparing three COVID-19 vaccination protocols in Soth Korea Frontiers in Immunology, 2022, 13: 968105.	초록보기

  해당 관련 논문목록과 초록보기 링크 제공

  Cross-neutralization between vaccine and circulating wild-type mumps viruses in Korea Vaccine, 2021, 39.13: 1870-1876.

  초록보기

• 정책 활용 성과 및 사례(``21~``24년)
  

  국내 도입 코로나19 백신 접종자 면역원성 분석 결과 발표(``21.7.26.)

  

  국내 코로나19 백신접종군 대상 백신별 항체조사 결과 발표(``21.11.17.)

  

  백신 3차 접종 후 오미크론, 델타변이에 대한 중화항체 효과 확인 결과 발표(``22.1.20.)

  

  전국 단위 항체 양성률 조사 결과 발표(``22.9.)

  

  전국 단위 항체 양성률 2차 조사 결과 발표(``23.1.)

  

  전국 단위 항체 양성률 3차 조사 결과 발표(``23.8.)

  

  전국 단위 항체 양성률 조사 참여자 대상 중화항체 분석 결과 발표(``24.1.)